Aspire Private Capital’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Aspire Private Capital’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-900	Closed	–	–	692
2022 Q3	$0	Hold	900	–	–	﹤0.01%	702
2022 Q2	$0	Hold	900	–	–	﹤0.01%	679
2022 Q1	$1K	Hold	900	–	–	﹤0.01%	590
2021 Q4	$2K	Hold	900	–	–	﹤0.01%	563
2021 Q3	$4K	Hold	900	–	–	﹤0.01%	434
2021 Q2	$4K	Buy	+900	New	+$4.58K	﹤0.01%	443

Aspire Private Capital's LOGC Position: Q4 2022 in Review

Aspire Private Capital sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 900 shares.

Aspire Private Capital first reported a position in LOGC in Q2 2021 and held it in 6 quarters. The position peaked at $4K in Q3 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Aspire Private Capital reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Aspire Private Capital sold 900 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
Aspire Private Capital first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Aspire Private Capital's LogicBio Therapeutics, Inc. Common Stock position peaked at $4K in Q3 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Aspire Private Capital's 13F filing for Q4 2022, filed 14 Feb 2023.